Medicine
New program supports femtech entrepreneurs
TechTransfer
EPFL
Thirty startups have raised CHF 60 million in funding through Tech4Eva, continental Europe’s first program designed specifically for entrepreneurs in the field of femtech, or technology for women’s health. On 7 December, Switzerland’s first femtech conference will mark the end of Tech4Eva’s inaugural year – and kick off the next funding round.
Harnessing the organisation of the cell surface
Research
ETH Zurich
Scientists at ETH Zurich have developed a new method to determine how proteins are organised on the surface of cells. Insights gained with the technology could lead to the development of novel drugs to fight cancer.
New catalysts for pharmaceutical companies
TechTransfer
PSI
In partnership with Roche, PSI scientists are developing new, potentially more efficient catalysts for manufacturing active substances for drug therapies.
Proton therapy: a success story that started 25 years ago
TechTransfer
PSI
25 November 1996: a world first for PSI’s Center for Proton Therapy in treating a cancer patient using the spot-scanning technique. Meanwhile this technique has become a standard procedure worldwide and since 1996 has been used to treat around 2000 cancer patients at PSI alone – over a third of them children and young people. The fact that the success story started at PSI was more than just a coincidence.
EPFL Part of New Alliance for Equal Access to Dialysis Therapy
TechTransfer
EPFL
The dire need of dialysis therapies in low- and middle-income countries has prompted the creation of an interdisciplinary and international alliance that brings together experts from key organizations including EPFL.
A digital reconstruction of the brain's power source
Research
EPFL
The EPFL Blue Brain Project has created the first digital reconstruction of the Neuro-Glia-Vascular Architecture providing a new framework to study brain function in health and disease. The study, published in Cerebral Cortex, represents a major milestone because they can now reconstruct the architecture of non-neuronal entities such as blood vessels and the supporting cells called glia. These reconstructions of the brain tissue provide a sub-micron precise framework needed to simulate the molecular interactions relevant to understanding how neurons are supported and nurtured. They can also be used to investigate how drugs interact and explore how neurodegenerative diseases arise.
Page 6 of 27